A groundbreaking application of CRISPR gene-editing technology has demonstrated remarkable success in treating a patient with a life-threatening, multidrug-resistant E. coli infection following a kidney transplant. The investigational therapy, known as SNIPR001, was administered under a single-patient emergency investigational new drug (eIND) application, marking a significant milestone in the fight against antimicrobial resistance (AMR).
The patient, a 65-year-old individual who had undergone a kidney transplant, developed a severe and aggressive form of E. coli malakoplakia. This rare condition is characterized by the persistence of bacteria within cells and proved resistant to conventional antibiotic treatments. Despite initial interventions, the infection progressed, leading to the formation of a significant mass and persistent lesions. In a desperate bid to combat the escalating threat, the medical team at the University of California San Diego (UCSD) sought and received approval for the emergency use of SNIPR001, a novel CRISPR-armed phage therapeutic developed by Danish biotech company SNIPR Biome.
The subsequent recovery of the patient, detailed in a peer-reviewed case report published in Clinical Infectious Diseases, offers a powerful testament to the potential of gene-editing approaches in addressing some of the most challenging infectious diseases. This development not only provides a beacon of hope for individuals facing similar untreatable infections but also underscores the accelerating innovation within the AMR landscape.
A Patient’s Ordeal: From Transplant to Untreatable Infection
The patient’s medical journey began with a kidney transplant, a procedure aimed at restoring vital organ function. However, post-transplant, the individual developed a complication that would ultimately become a critical health crisis: a multidrug-resistant E. coli infection. The specific manifestation, E. coli malakoplakia, is a particularly insidious disease. It involves the formation of characteristic yellowish lesions composed of macrophages that have ingested undigested bacterial material. These lesions, in this case, arose from the bladder wall and prostate, creating a substantial intra-abdominal mass.
The standard of care for such infections typically involves a course of powerful antibiotics. However, in this instance, the E. coli strain exhibited a high degree of resistance, rendering the prescribed antibiotics ineffective. As the infection persisted and worsened, the patient’s condition became increasingly precarious, highlighting the growing global threat of AMR, where common infections can once again become deadly due to the ineffectiveness of existing treatments. The failure of conventional therapies necessitated the exploration of experimental and innovative treatment modalities.
The Dawn of a New Era: SNIPR001 Enters the Fray
Faced with a dire prognosis and limited options, the medical team at UCSD, in collaboration with SNIPR Biome, initiated a compassionate-use treatment protocol. This involved the administration of SNIPR001, an investigational therapy that harnesses the precision of CRISPR gene-editing technology. SNIPR001 is not a traditional small molecule drug or antibody; rather, it is a sophisticated bacteriophage-based therapeutic. Bacteriophages are viruses that naturally infect bacteria, and SNIPR Biome has engineered them to carry CRISPR-Cas systems.
The CRISPR-Cas system acts like a molecular scissor, capable of precisely targeting and cutting specific DNA sequences. In the case of SNIPR001, the engineered phages are designed to identify and disable the genes within the E. coli bacteria that confer antibiotic resistance. This targeted approach aims to neutralize the pathogen without causing widespread collateral damage to the patient’s beneficial gut microbiome, a common concern with broad-spectrum antibiotics.
The administration of SNIPR001 was approved through a single-patient emergency investigational new drug (eIND) application, a regulatory pathway that allows for the use of unapproved investigational drugs in life-threatening situations where no satisfactory alternative exists. This expedited process underscores the urgency and severity of the patient’s condition and the potential of the investigational therapy.
A Remarkable Turnaround: Clinical Data Reveals Dramatic Recovery
The impact of SNIPR001 treatment was observed remarkably quickly. Within just one week of initiating the therapy, the patient’s abdominal cutaneous lesions, a visible manifestation of the infection, showed marked improvement. This early positive response was a significant indicator of the therapy’s efficacy.
Further evidence of SNIPR001’s success emerged in the subsequent weeks. By the four-week mark, several of the patient’s lesions had completely healed. Simultaneously, imaging studies revealed a substantial reduction in the size of the intra-abdominal mass. At the commencement of treatment, this mass measured an imposing 744.6 cm³. By eight weeks post-initiation, it had decreased to 373.4 cm³, representing a significant reduction.
The positive trajectory continued over the ensuing months. After a year of follow-up, the intra-abdominal mass had shrunk further to an astonishing 82 cm³, signifying an overall reduction of 89% from its initial size. This dramatic shrinkage, coupled with the healing of lesions and the apparent eradication of the multidrug-resistant E. coli, points to a profound and sustained therapeutic effect.
The comprehensive clinical data, meticulously collected and analyzed, has been formally published in a peer-reviewed expanded access case report in Clinical Infectious Diseases on August 11th. This publication lends significant scientific credibility to the findings and allows for broader dissemination within the medical and research communities.
Official Responses: A Milestone for SNIPR Biome and a Glimpse into the Future
The successful outcome of this compassionate-use case has elicited enthusiastic responses from both the treating physicians and the developers of SNIPR001. Dr. Christian Grøndahl, CEO and co-founder of SNIPR Biome, hailed the case report as an "important clinical milestone for SNIPR001." He emphasized the therapy’s potential to address difficult-to-treat, drug-resistant E. coli infections, a growing public health concern.
"We are grateful to the investigators at UC San Diego and to the patient and care team involved in this compassionate-use case," Dr. Grøndahl stated. "This provides valuable clinical insight into the potential role of SNIPR001 beyond prevention of bloodstream infections." His remarks highlight that while SNIPR001 is also being developed for prophylactic use, this case demonstrates its therapeutic capabilities in treating active, severe infections.
The patient was treated by infectious disease investigators at UC San Diego, operating under the eIND application. SNIPR Biome views this data as a strong validation of SNIPR001’s translational potential in a real-world, compassionate-use setting.
SNIPR001 is currently undergoing further clinical development. It is being investigated as a CRISPR-armed phage therapeutic, initially for the prevention of E. coli bloodstream infections in patients with hematological malignancies. However, the success in this case suggests its potential application in treating active E. coli infections may also be a significant avenue for exploration.
The company is actively engaged in a randomized, double-blind, placebo-controlled Phase Ib/IIa trial (NCT06938867). This trial is designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered SNIPR001 in 24 patients with hematological cancer. Building on previous research, SNIPR had previously completed a Phase Ia trial (NCT05277350) in the US. This earlier study demonstrated the safety of SNIPR001 and confirmed its ability to engage with E. coli in the gut of healthy volunteers without disrupting the overall gut microbiome, a crucial factor for long-term gut health.
Broader Implications: CRISPR as a Powerful Weapon Against AMR
The success of SNIPR001 in this challenging case resonates with broader trends and expert opinions regarding the role of CRISPR technology in combating antimicrobial resistance. A recent report by GlobalData, titled "CRISPR Gene Editing in Infectious Diseases: Market Overview," identifies programmable gene-editing technologies as key players in addressing unmet needs in both viral and bacterial infections. Companies like Excision BioTherapeutics, BDGene Therapeutics, Locus Biosciences, and SNIPR Biome are at the forefront of this innovation.
The GlobalData report specifically highlights the growing traction of CRISPR-enhanced phage therapy as a strategy to combat AMR. It notes that companies such as Locus Biosciences and SNIPR Biome are developing engineered bacteriophages designed to selectively eliminate antibiotic-resistant E. coli, with clinical trials already underway.
However, the report also acknowledges the hurdles that lie ahead. Abigail Harris, an infectious disease analyst at GlobalData, points out that while early trial results are encouraging, key opinion leaders have identified challenges such as delivery mechanisms, potential immune responses, and regulatory uncertainties as significant obstacles to widespread adoption. The development of novel delivery platforms, including lipid nanoparticles and adeno-associated viruses (AAVs), is actively being pursued to ensure safe and targeted in vivo gene editing.
Despite these challenges, the prevailing sentiment is one of optimism. As Harris concludes, "CRISPR-based therapeutics hold the potential to shift the treatment paradigm for some of the most persistent infections worldwide. As more data emerges from clinical trials, gene-editing-based approaches in infectious disease are expected to see increased momentum, investment, and regulatory support."
The case of SNIPR001 serves as a compelling real-world demonstration of this potential. It offers a tangible example of how cutting-edge gene-editing technology can be deployed, even in emergency situations, to overcome the formidable challenge of multidrug-resistant infections, offering renewed hope in the global fight against antimicrobial resistance.
About the Author
